SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) DECEMBER 22, 1995
ENZON, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") has granted Rhone-Poulenc Rorer
Inc. ("RPR") a worldwide, non-exclusive license to use Enzon's Single-Chain
Antigen-Binding ("SCA") protein technology for intracellular expression of
SCA proteins and for targeted vectors in the field of cell and gene
therapy. RPR Gencell, the cell and gene therapy division of RPR, is
planning to apply this technology to its in vivo and ex vivo gene therapy
programs in cancer, cardiovascular disease and immunology. RPR paid Enzon
a $1,000,000 license fee and will make additional payments upon the
achievement of specified product development milestones. RPR will also pay
Enzon a royalty based upon sales of products incorporating the Enzon
technology.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: February 7, 1996
ENZON, INC.
(Registrant)
By: /S/ KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial Officer
